Alkemist Bio
Founded 2023 · 6 employees on LinkedIn · 4 known investors
ALKemist Bio develops immunotherapies targeting ALK-positive cancers, using chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) engineered T cells to eliminate treatment-resistant tumors. The company focuses on oncology precision therapies for aggressive cancers including neuroblastoma and non-small cell lung cancer.
Investors · 4
Frequently asked questions
- What does Alkemist Bio do?
- ALKemist Bio develops immunotherapies targeting ALK-positive cancers, using chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) engineered T cells to eliminate treatment-resistant tumors. The company focuses on oncology precision therapies for aggressive cancers including neuroblastoma and non-small cell lung cancer.
- Who are Alkemist Bio's investors?
- Alkemist Bio's investors include Claris Ventures, Club degli Investitori, Italian Angels for Growth, LIFTT.